Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose-response.

Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ

History

Long-term outcomes of

Principal Investigator

Mesolimbic interaction

Optimal Medical Therap

Evaluation of bivalent

See All (8) pages

Announcement

You can now add alternative names! Click here to add other names that you've published under.

Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose-response.

Gruber WC, Darden PM, Still JG, Lohr J, Reed G, Wright PF. Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose-response. Vaccine. 1997 Aug-Sep; 15(12-13):1379-84.

View in: PubMed

subject areas

Antibodies, Viral
Child, Preschool
Dose-Response Relationship, Immunologic
Double-Blind Method
Humans
Infant
Influenza A virus
Influenza Vaccines
Vaccines, Attenuated

authors with profiles

Paul Darden